Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
2.480
-0.580 (-18.95%)
At close: Aug 28, 2025, 4:00 PM
2.520
+0.040 (1.61%)
After-hours: Aug 28, 2025, 7:59 PM EDT
Cognition Therapeutics Employees
As of December 31, 2024, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,178,321
Market Cap
182.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 0 | - |
| Dec 31, 2023 | 28 | 3 | 12.00% |
| Dec 31, 2022 | 25 | 4 | 19.05% |
| Dec 31, 2021 | 21 | 1 | 5.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CGTX News
- 1 day ago - Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 2 days ago - Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 2 days ago - Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating - Seeking Alpha
- 16 days ago - Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewsWire
- 7 weeks ago - Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease - GlobeNewsWire